7-羟基-1-萘羧酸 | 2623-37-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 中文名称: 7-羟基-1-萘羧酸
• 中文别名: 7-羟基-1-萘甲酸
• 英文名称: 7-hydroxy-1-naphthalenecarboxylic acid
• 英文别名: 7-hydroxy-[1]naphthoic acid；7-Hydroxy-[1]naphthoesaeure；7-Oxy-naphthalin-carbonsaeure-(1)；7-Hydroxy-<1>naphthoesaeure；7-Hydroxy-α-naphthoesaeure；2-Hydroxy-naphthoesaeure-(8)；7-Hydroxy-1-naphthoic acid；7-hydroxynaphthalene-1-carboxylic acid
• CAS: 2623-37-2
• 化学式: C₁₁H₈O₃
• 分子量: 188.183
• InChiKey: XABCHXCRWZBFQX-UHFFFAOYSA-N

物化性质

• 熔点：
  253-254 °C
• 沸点：
  445.7±18.0 °C(Predicted)
• 密度：
  1.399±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  57.5
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 海关编码：
  2918290000

反应信息

• 作为反应物：
  描述：

  7-羟基-1-萘羧酸 在 ammonium hydroxide 、 ammonium sulfite 作用下， 生成 7-氨基-1-萘甲酸
  参考文献：
  名称：

  Sur les acides7-halogéno-1-naphtoïques

  摘要：

  DOI：

  10.1002/hlca.193802101187
• 作为产物：
  描述：

  7-methoxynaphthalene-1-carboxylic acid 在 氢溴酸 、 溶剂黄146 作用下， 生成 7-羟基-1-萘羧酸
  参考文献：
  名称：

  The Synthesis of Phenanthrene and Hydrophenanthrene Derivatives. V. The Addition of Dienes to Cyclic α,β-Unsaturated Esters

  摘要：

  DOI：

  10.1021/ja01302a069

文献信息

• [EN] SUBSTITUTED 2-NAPHTHOIC ACIDS AS ANTAGONISTS OF GPR105 ACTIVITY<br/>[FR] ACIDES 2-NAPHTOÏQUE SUBSTITUÉS EN TANT QU'ANTAGONISTES DE L'ACTIVITÉ DE GPR105
  申请人：MERCK FROSST CANADA LTD

  公开号：WO2009070873A1

  公开（公告）日：2009-06-11

  Substituted 2-naphthoic acids of structural formula I are effective as antagonists of the biological activity of GPR105 protein. They are useful for the treatment, control or prevention of disorders responsive to antagonism of this receptor, such as diabetes, particularly, Type 2 diabetes, insulin resistance, hyperglycemia, lipid disorders, obesity, atherosclerosis, and conditions associated with the Metabolic Syndrome.

  结构式I中的2-萘甲酸替代物对GPR105蛋白的生物活性具有拮抗作用。它们可用于治疗、控制或预防对该受体拮抗有响应的疾病，如糖尿病，特别是2型糖尿病，胰岛素抵抗，高血糖，脂质紊乱，肥胖，动脉粥样硬化以及与代谢综合征相关的疾病。
• Method for producing naphthalene carboxylic acid amide compound
  申请人：Wakamori Hiroyuki

  公开号：US20080045720A1

  公开（公告）日：2008-02-21

  The present invention provides a method for producing a naphthalenecarboxylic acid amide compound represented by formula [1] comprising, reacting a naphthalenecarboxylic acid halide compound represented by formula [2] with ammonium acetate in a solvent having an ether bond. According to the method of the present invention, a naphthalene carboxylic acid amide compound can be obtained at high yield and at low cost.

  本发明提供了一种制备萘甲酸酰胺化合物（由式[1]表示）的方法，包括将由式[2]表示的萘甲酸卤化物与醋酸铵在具有醚键的溶剂中反应。根据本发明的方法，可以以高收率和低成本获得萘甲酸酰胺化合物。
• INCLUSION COMPLEX CONTAINING EPOXY RESIN COMPOSITION FOR SEMICONDUCTOR ENCAPSULATION
  申请人：Ono Kazuo

  公开号：US20100179250A1

  公开（公告）日：2010-07-15

  It is to improve the storage stability of a sealant, to retain the flowability of the sealant when sealing, and to achieve an effective curing rate of the sealant by heating to be applicable as a sealant for delicate semiconductors. It is an epoxy resin composition for sealing a semiconductor, comprising the following component (A) and component (B). (A) an epoxy resin, (B) a clathrate complex comprising (b1) an aromatic carboxylic acid compound, and (b2) at least one imidazole compound represented by formula (II) (wherein R 2 represents a hydrogen atom, etc.; R 3 to R 5 represent a hydrogen atom, etc.).

  这是为了改善密封剂的储存稳定性，保持密封时密封剂的流动性，并通过加热实现密封剂的有效固化速率，以适用于精细半导体的密封剂。它是一种用于密封半导体的环氧树脂组合物，包括以下组分（A）和组分（B）。（A）环氧树脂，（B）包括（b1）芳香羧酸化合物和（b2）至少一种由式（II）表示的咪唑化合物的笼形复合物（其中R2表示氢原子等；R3至R5表示氢原子等）。
• SUBSTITUTED 2-NAPHTHOIC ACIDS AS ANTAGONISTS OF GPR105 ACTIVITY
  申请人：Belley Michel

  公开号：US20100298347A1

  公开（公告）日：2010-11-25

  Substituted 2-naphthoic acids of structural formula are effective as antagonists of the biological activity of GPR105 protein. They are useful for the treatment, control or prevention of disorders responsive to antagonism of this receptor, such as diabetes, particularly, Type 2 diabetes, insulin resistance, hyperglycemia, lipid disorders, obesity, atherosclerosis, and conditions associated with the Metabolic Syndrome.

  具有以下结构式的2-萘甲酸替代物是GPR105蛋白生物活性的拮抗剂，对于治疗、控制或预防对此受体的拮抗作用有响应的疾病非常有效，包括糖尿病，特别是2型糖尿病，胰岛素抵抗，高血糖，脂质异常，肥胖症，动脉粥样硬化以及与代谢综合征相关的疾病。
• Synthesis and preclinical evaluation of novel 18F-labeled fibroblast activation protein tracers for positron emission tomography imaging of cancer-associated fibroblasts
  作者：Hui Zhou、Jiawei Zhong、Simin Peng、Yang Liu、Peipei Tang、Zhikai Cai、Lu Wang、Hao Xu、Kongzhen Hu

  DOI：10.1016/j.ejmech.2023.115993

  日期：2024.1

  Fibroblast activation protein (FAP) is overexpressed in cancer-associated fibroblasts in more than 90% of epithelial tumors. Several radiotracers targeting FAPs have been used in clinical settings in recent years. However, the number of 18F-labeled FAP tracers is still limited. Herein, we aimed to develop 18F-labeled FAP tracers with optimized pharmacokinetics. Labeling precursors (NOTA-DD-FAPI and

  成纤维细胞激活蛋白 (FAP) 在超过 90% 的上皮性肿瘤的癌症相关成纤维细胞中过度表达。近年来，几种针对 FAP 的放射性示踪剂已在临床环境中使用。然而， 18 F标记的FAP示踪剂的数量仍然有限。在此，我们的目标是开发具有优化药代动力学的18 F 标记 FAP 示踪剂。合成标记前体（NOTA-DD-FAPI 和 NOTA-PD-FAPI）并用氟-18 标记。前体 NOTA-DD-FAPI (IC 50 = 0.21 ± 0.06 nM) 和 NOTA -PD-FAPI (IC 50 = 0.13 ± 0.07 nM) 与 NOTA-FAPI-42 (IC 50 = 0.66 ± 0.19纳米）。新型18 F 标记的 FAP 示踪剂在体外表现出特异性摄取、高内化分数和低细胞流出。与临床使用的示踪剂[ 18 F]AlF-FAPI-42相比，新型18 F标记的FAP示踪剂，特别是具有较高肿瘤背景比的[